New data have shown that GSK’s Shingrix provides at least 10 years of protection against shingles in adults aged 50 years and over.
In the primary endpoint, the interim data demonstrated overall efficacy of greater than 80% over the follow-up period of approximately six to 10 years after initial vaccination.
The interim analysis data from the ZOSTER-049 (ZOE-LTFU) extension study was presented at the IDWeek congress in Washington DC, US.
The study followed two Phase III clinical trials ZOE-50 and ZOE-70, which showed that vaccine efficacy was 97% in adults 50 years and above and 91% in adults 70 years and above over a follow-up period of approximately four years.
The ZOE-LTFU study is ongoing and will continue to evaluate the longer-term efficacy, immunogenicity and safety of the vaccine.
Dr Javier Díez-Domingo, Principal Investigator, FISABIO (Foundation for the Promotion of Health and Biomedical Research of the Valencian Community, Spain), said: “Shingles is a painful disease that one in three adults will develop in their lifetime. We can now – for the first time – confirm that the clinical benefit of the Recombinant Zoster Vaccine overall, continues for at least 10 years after vaccination, giving patients and their healthcare providers peace of mind about the duration of protection against shingles.”
The Recombinant Zoster Vaccine (RZV) is the first approved shingles vaccine to combine a non-live antigen with an adjuvant and may help overcome the natural age-related decline in immunity that contributes to the challenge of protecting adults aged 50 years and above from this disease.
